A new online resource is now available to help people recognize and find high quality care for alcohol use disorder, which affects more than 15 million adults in the United States. The Alcohol Treatment Navigator, designed by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), part of the National Institutes of Health, is a comprehensive, yet easy-to-use tool to help individuals and their loved ones navigate the often-complicated process of choosing treatment for alcohol problems. With many treatment options available, the navigator makes the search easier by telling them what they need to know - and what they need to do – to find appropriate, quality care.
“We developed this tool to help address the alcohol ‘treatment gap,’” said NIAAA Director George F. Koob, Ph.D. “In any given year, less than 10 percent of individuals diagnosed with alcohol use disorder receive treatment, and many of them do not receive the type of care that best fits their needs. A big reason for that, we believe, is that people with alcohol use disorder often don’t know where to turn for help. The Alcohol Treatment Navigator offers a comprehensive strategy to help people search for professionally-led, evidence-based alcohol treatment, which should improve their chances for success.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8179051-niaaa-alcohol-treatment-navigator/
Federally funded research that provides a deep understanding of cancer is spurring advances against many types of the disease. With a strong bipartisan commitment from Congress to keep investment in biomedical research a national priority, we can accelerate our pace of progress and save more lives from cancer, according to the seventh annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
Basic research in the fields of immunology and cancer genetics has recently been harnessed to develop two new forms of cancer treatment: immunotherapy and precision medicine. As detailed in the report, the utility of these treatments is expanding rapidly. In May 2017, the U.S. Food and Drug Administration (FDA) heralded a new dawn for precision medicine when it approved the immunotherapeutic pembrolizumab (Keytruda) for treating patients with any solid tumor harboring specific genetic characteristics. This is the first anticancer therapeutic approved based on cancer biomarkers rather than the location in the body where the cancer originated.
To view the multimedia release go to:
https://www.multivu.com/players/English/8155051-aacr-cancer-progress-report-2017/
Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, announced today that NFL analyst and philanthropist, Deion Sanders, the only athlete to play in both the Super Bowl™ and World Series™, will serve as a brand ambassador for BOTOX® Cosmetic.
Harnessing Sanders’ trademark swagger, style and humor, Allergan also released two videos featuring Sanders sharing how he addressed his moderate to severe frown lines and crow’s feet with BOTOX® Cosmetic and showing men everywhere how the treatment may be right for them as well.
To view the multimedia release go to:
https://www.multivu.com/players/English/8174251-allergan-deion-sanders-botox/
Blood cancers are the third leading cause of cancer deaths in the U.S. However, many Americans are unaware of the impact of these cancers, including leukemia, lymphoma and myeloma, which affect the bone marrow, the blood cells, the lymph nodes and other parts of the lymphatic system.
A new survey commissioned by The Leukemia & Lymphoma Society (LLS) reveals more than four in five adults (82%) are surprised that blood cancers are the third leading cancer killer of Americans. Further, nearly four in five adults (78%) are surprised that acute lymphocytic leukemia (ALL) is the most common cancer in children and young adults under age 20.
To view the multimedia release go to:
https://www.multivu.com/players/English/8128551-lls-blood-cancer-awareness-month/
In an effort to improve outcomes for patients with some of the deadliest childhood cancers, St. Jude Children’s Research Hospital scientists have created the world’s largest collection of pediatric solid tumor samples, drug-sensitivity data and related information and have made the resource available at no charge to the global scientific community.
St. Jude and the Howard Hughes Medical Institute collaborated to create the resource, known as the Childhood Solid Tumor Network. The work is reported today as an advance online publication in the scientific journal Nature.
“Survival rates for children with recurrent solid tumors have not improved significantly in more than 20 years and remain below 30 percent,” said corresponding author Michael Dyer, Ph.D., chair of the St. Jude Department of Developmental Neurobiology and a Howard Hughes Medical Institute investigator. “This research will change that by promoting scientific collaboration to leverage the efforts of researchers worldwide to advance understanding and ultimately treatment of pediatric solid tumors.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8121952-st-jude-childrens-childhood-solid-tumor-network/
Kiehl’s Since 1851, the 166-year-old skincare company, has used its fleet of iconic motorcycles to raise funds and awareness for AIDS research and awareness for the eighth year in a row. Kiehl’s LifeRide for amfAR, a charitable motorcycle ride from Minneapolis to Nashville, July 31 to Aug. 7, has already raised more than $125,000 for amfAR, The Foundation for AIDS Research and fundraising will continue through August.
Kiehl’s President Chris Salgardo and amfAR CEO Kevin Robert Frost led the 1,200 mile, 8-day journey, accompanied by actors Tyler Posey, Gilles Marini and Ian Bohen, tattoo artist Luke Wessman, and TV hosts Anthony Carrino and Grant Reynolds. Over eight days, the riders participated in nine public events, meeting customers and educating about HIV/AIDS research.
To view the multimedia release go to:
https://www.multivu.com/players/English/8160451-kiehls-liferide-for-amfar-aids-research-liferide8/
Each day in the U.S. 91 people die from an opioid-related overdose, and the numbers are increasing. In observance of International Overdose Awareness Day on August 31, American Addiction Centers (AAC) and Recovery Brands are launching a nationwide awareness campaign on how to prevent deaths from opioid overdoses. The campaign features shareable online resources, including an animation video about how an overdose impacts a body, an infographic about how to administer overdose medication, and powerful videos of survivors sharing the life-saving lessons they learned during their darkest hours.
“This is a meaningful endeavor as we partner with our parent company, AAC, in order to present several life-saving resources for people impacted by addiction,” said Ruchi Dhami, director of market insights and development at Recovery Brands, a provider of digital addiction treatment resources. “Since such a large amount of individuals look for information online about addiction and treatment, we wanted to ensure comprehensive education surrounding opioid overdoses existed and is easily accessible for individuals and families impacted by addiction.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8130951-american-addiction-centers-opioid-overdose/
Today, WebMD released Advanced Breast Cancer: Courage, Comfort and Care with Robin Roberts, a five-part video series developed in partnership with Roberts and her independent production company, Rock’n Robin Productions. The series dives into the daily coping strategies of women living with advanced breast cancer, plus the families and friends who provide encouragement and support, and includes insights from medical experts leading the charge to combat the disease.
Over 255,000 people in the United States will be diagnosed with invasive breast cancer this year, and over 41,000 will die, with metastatic breast cancer being the leading cause of those fatalities. Despite these staggering statistics, there are signs of hope. Treatments for metastatic breast cancer are improving, and they continue to help people with the disease live longer and healthier lives.
To view the multimedia release go to:
https://www.multivu.com/players/English/8154851-webmd-advanced-breast-cancer-robin-roberts/
23andMe, working in collaboration with the Milken Institute and Lundbeck, today announced that they have commenced enrollment for a first-of-its kind genetic study designed to gain understanding of the underlying biology of major depressive and bipolar disorders. This study will combine cognitive assessments with genetic data and survey responses to assess how genes influence brain processes – such as attention, decision-making and visual perception – in individuals who live with these serious mental health conditions.
“We know genetics play a role in the development of depression and bipolar, however there is a long pathway from our genes to the manifestation of complex diseases like these,” said Emily Drabant Conley, PhD., Vice President of Business Development at 23andMe. “We need to look at these conditions in a more comprehensive way to advance our understanding. By studying cognitive function alongside genetics and other environmental variables on a massive scale, we hope to take a significant step forward in the study of depression and bipolar.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8150951-23andme-genetic-study-depression-bipolar-disorders/
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that its first doses of the Fluzone® (Influenza Vaccine) portfolio for the 2017-2018 influenza (“flu”) season have been released by the U.S. Food and Drug Administration (FDA). Sanofi Pasteur has begun distributing initial shipments, representing the first of nearly 70 million total doses of seasonal influenza vaccine manufactured by the company for this upcoming influenza season. Widespread shipment of Fluzone Quadrivalent, Fluzone High-Dose and Fluzone Intradermal Quadrivalent vaccine to health care provider offices, pharmacies and other immunizers will begin in early August to support fall immunization campaigns.
“As we enter the Swiftwater site’s 120th year, it reminds us of our innovation and growth as we came to understand the science of influenza and its impact on human health,” said David P. Greenberg, M.D., Associate Vice President and Regional Medical Head North America, Sanofi Pasteur. “Influenza can be especially severe for the most vulnerable populations, including the elderly, young children and those with compromised immune systems; however, it can also have a serious health impact on otherwise healthy individuals. Sanofi Pasteur is and always has been deeply committed to improving public health by continuously striving to develop new vaccines and on improving existing ones.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8081151-sanofi-pasteur-influenza-vaccine-first-shipment-2017/
Today, WebMD released In Their Own Words: Moving Beyond Migraine with Robin Roberts, a new five-part video series that sheds light on the debilitating nature of migraine and the impact it has on all aspects of a sufferer’s personal and professional life.
To learn more about treatments and the individuals featured in In Their Own Words: Moving Beyond Migraine with Robin Roberts, visit: to www.webmd.com/insidemigraines.
Moving Beyond Migraine follows the lives of Jennifer, a public school administrator who has lived with intense migraine headaches for over 20 years; Kate, a 20-year-old college student with debilitating migraines that have run in her family for generations; Melanie, whose intense migraine condition has altered the dynamics of her nine year marriage; and Lynn, who after suffering from migraine for 50 years, shares how a clinical trial for a new treatment called CGRP targeted therapy is finally providing her with some relief.
To view the multimedia release go to:
https://www.multivu.com/players/English/7579759-robin-roberts-moving-beyond-migraine/
BloodCenter of Wisconsin’s Diagnostic Laboratories, part of Versiti, today announced the launch of seven hematology genetics test panels. The new test panels enhance and expand BloodCenter’s genetic testing capability to include a vast array of non-malignant hematology disorders, including platelet function disorders, inherited thrombocytopenia and congenital neutropenias, providing one of the most comprehensive test menus in hematology.
BloodCenter’s integration of functional and genetic testing provides a unique approach to diagnosing complex hematology disorders, providing a comprehensive review of each patient for improved patient care and outcomes.
To view the multimedia release go to:
https://www.multivu.com/players/English/8126851-bloodcenter-of-wisconsin-versiti-hematology-genetics-test-panels/
